Back to VANGUARD GROUP INC VANGUARD GROUP INC

LCTXLCTX
6 quarters

Position history for VANGUARD GROUP INCVANGUARD GROUP INC's holdings in LINEAGE CELL THERAPEUTICS IN

VANGUARD GROUP INC holds 9.6M shares of LCTX (LINEAGE CELL THERAPEUTICS IN), worth $16.1M as of 2025-Q4. The position was increased (+7.1% shares). LCTX represents 0.0% of VANGUARD GROUP INC's portfolio.

Current Value

$16.1M

Current Shares

9.6M

Total Value Change

+$8.3M

Total Shares Change

+1M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2025-Q4
Latest
Increased
9.6M
+7.1%
$16.1M0.0%$1.67
30
2025-Q3
Increased
9M
+6.2%
$15.2M0.0%$1.69
30
2025-Q2
Decreased
8.5M
-4.9%
$7.7M0.0%$0.91
0
2025-Q1
Increased
8.9M
+3.3%
$4M0.0%$0.45
28
2024-Q4
Increased
8.6M
+0.4%
$4.3M0.0%$0.50
27
2024-Q3
First report
8.6M
-
$7.8M0.0%$0.91
0

Other major holders of LCTX: BlackRock, Inc., STATE STREET CORP, VANGUARD CAPITAL MANAGEMENT LLC, BlackRock Finance, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used